Privium Fund Management’s UroGen Pharma URGN Stock Holding History

Privium Fund Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.73M	Sell	210,000 -28,122	-12%	-$762K	1.42%	21
2026 Q1	$4.28M	Buy	238,122 +23,500	+11%	+$471K	0.89%	25
2025 Q4	$5.03M	Buy	214,622 +18,000	+9%	+$390K	0.93%	22
2025 Q3	$3.92M	Buy	196,622 +89,000	+83%	+$1.6M	0.71%	23
2025 Q2	$1.4M	Hold	107,622	–	–	0.3%	25
2025 Q1	$1.19M	Buy	107,622 +79,931	+289%	+$852K	0.31%	31
2024 Q4	$295K	Buy	+27,691	New	+$332K	0.07%	53

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Privium Fund Management's URGN Position: Q2 2026 in Review

Privium Fund Management reduced its UroGen Pharma (URGN) stake by 12% in Q2 2026, selling an estimated $762K and leaving 210,000 shares worth $7.73M. The position accounts for 1.42% of the portfolio, ranked #21.

Privium Fund Management first reported a position in URGN in Q4 2024 and has held it in 7 quarters since. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Privium Fund Management held 210,000 shares of UroGen Pharma worth $7.73M as of Q2 2026.
Privium Fund Management sold 28,122 UroGen Pharma shares in Q2 2026, an estimated $762K.
UroGen Pharma made up 1.42% of Privium Fund Management's portfolio in Q2 2026, its #21 holding.
Privium Fund Management first reported a position in UroGen Pharma in Q4 2024 and has held it in 7 quarters since.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.